Value of the application of computed tomography‐based radiomics for preoperative prediction of unfavorable pathology in initial bladder cancer

To construct and validate unfavorable pathology (UFP) prediction models for patients with the first diagnosis of bladder cancer (initial BLCA) and to compare the comprehensive predictive performance of these models.

[1]  M. Maggi,et al.  Radiogenomics in Renal Cancer Management—Current Evidence and Future Prospects , 2023, International journal of molecular sciences.

[2]  A. McWilliam,et al.  Bladder Cancer Radiation Oncology of the Future: Prognostic Modelling, Radiomics, and Treatment Planning With Artificial Intelligence. , 2023, Seminars in radiation oncology.

[3]  Zixuan Song,et al.  From past to future: Bibliometric analysis of global research productivity on nomogram (2000–2021) , 2022, Frontiers in Public Health.

[4]  Fan Lin,et al.  The role of radiomics with machine learning in the prediction of muscle-invasive bladder cancer: A mini review , 2022, Frontiers in Oncology.

[5]  A. Kishan,et al.  NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  R. Autorino,et al.  Radiomics in prostate cancer: an up-to-date review , 2022, Therapeutic advances in urology.

[7]  J. Ye,et al.  Feasibility Study on Predicting Recurrence Risk of Bladder Cancer Based on Radiomics Features of Multiphase CT Images , 2022, Frontiers in Oncology.

[8]  Sicong Wang,et al.  Development of a MRI-Based Radiomics Nomogram for Prediction of Response of Patients With Muscle-Invasive Bladder Cancer to Neoadjuvant Chemotherapy , 2022, Frontiers in Oncology.

[9]  X. Liu,et al.  CT-based radiomics for the preoperative prediction of the muscle-invasive status of bladder cancer and comparison to radiologists' assessment. , 2022, Clinical radiology.

[10]  Zhengyu Jin,et al.  CT-based radiomics to predict muscle invasion in bladder cancer , 2022, European Radiology.

[11]  Hailin Shen,et al.  Value of the Application of CE-MRI Radiomics and Machine Learning in Preoperative Prediction of Sentinel Lymph Node Metastasis in Breast Cancer , 2021, Frontiers in Oncology.

[12]  M. Milowsky,et al.  The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. , 2021, European urology.

[13]  A. Masson-Lecomte,et al.  European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). , 2021, European urology.

[14]  B. Song,et al.  Development and Validation of Noninvasive MRI‐Based Signature for Preoperative Prediction of Early Recurrence in Perihilar Cholangiocarcinoma , 2021, Journal of magnetic resonance imaging : JMRI.

[15]  Baojuan Li,et al.  Study Progress of Noninvasive Imaging and Radiomics for Decoding the Phenotypes and Recurrence Risk of Bladder Cancer , 2021, Frontiers in Oncology.

[16]  G. Valdes,et al.  Artificial intelligence and machine learning for medical imaging: A technology review. , 2021, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.

[17]  G. Novara,et al.  Nomograms in Urologic Oncology: Lights and Shadows , 2021, Journal of clinical medicine.

[18]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[19]  Alisa S. Bettermann,et al.  Uncovering the invisible—prevalence, characteristics, and radiomics feature–based detection of visually undetectable intraprostatic tumor lesions in 68GaPSMA-11 PET images of patients with primary prostate cancer , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Peng Du,et al.  Diagnostic Value of Inflammatory Factors in Pathology of Bladder Cancer Patients , 2020, Frontiers in Molecular Biosciences.

[21]  Zhengyu Jin,et al.  CT-based radiomics to predict the pathological grade of bladder cancer , 2020, European Radiology.

[22]  M. A. Shouman,et al.  A CT-based radiomics model to detect prostate cancer lymph node metastases in PSMA radioguided surgery patients , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  J. Witjes,et al.  European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. , 2020, European urology.

[24]  R. Autorino,et al.  Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. , 2018, European urology oncology.

[25]  M. Babjuk,et al.  Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016". , 2018, European urology focus.

[26]  P. Mariappan,et al.  Predicting Grade and Stage at Cystoscopy in Newly Presenting Bladder Cancers-a Prospective Double-Blind Clinical Study. , 2017, Urology.

[27]  B. Erickson,et al.  Machine Learning for Medical Imaging. , 2017, Radiographics : a review publication of the Radiological Society of North America, Inc.

[28]  M. Babjuk,et al.  The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. , 2016, European urology focus.

[29]  R. Thompson,et al.  Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. , 2014, European urology.

[30]  Sam S. Chang,et al.  Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy , 2014, BJU international.

[31]  C. Dinney,et al.  Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort , 2011, BJU international.

[32]  L. Martínez-Piñeiro,et al.  Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. , 2009, The Journal of urology.

[33]  H. Herr,et al.  Quality control in transurethral resection of bladder tumours , 2008, BJU international.

[34]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[35]  K. Grigor,et al.  Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. , 2010, European urology.

[36]  Yair Lotan,et al.  Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. , 2007, European urology.